JPMorgan Raises Upstream Bio Price Target to $9.00
Upstream Bio (NASDAQ:UPB) has had its price target increased to $9.00 by JPMorgan Chase & Co., representing a potential upside of 29.22% from the stock's current price.
This new target is up from the previous $8.00 estimate and was announced in a research report on Friday. The firm currently maintains a 'neutral' rating on the stock.
The stock's current price is $6.96, with 176,117 shares traded during midday trading on Friday. Upstream Bio has a market cap of $381.47 million and a beta of 1.26.